One acute promyelocytic leukemia patient underwent complete molecular remission with consistent presence of t (2; 3) (p25; q21) karyotype

Expert Opin Ther Targets. 2013 Oct;17(10):1115-8. doi: 10.1517/14728222.2013.832205. Epub 2013 Aug 30.

Abstract

Objectives: This study aimed to explore why one acute promyelocytic leukemia (APL) patient underwent complete molecular remission in the persistent presence of the t (2; 3) (p25; q21) karotype.

Methods: One APL patient overexpressed PML/RARα (bcr1) and WT1 genes in the presence of the Fms-like tyrosine kinase-internal tandem duplication mutation, while cytogenetics showed t (2; 3) (p25; q21) and t (15; 17) (q22; q21). Cytogenetics and molecular biology were monitored throughout the treatment.

Results: After 5 weeks of induction chemotherapy, this case gained complete molecular biology remission with the presence of t (2; 3) (p25; q21). This status was still present during the follow-up consolidate and maintenance therapy.

Conclusion: For this patient, t (2; 3) (p25; q21) may be one kind of balanced translocation that leads to miscarriages or causes abnormalities in children, unrelated to leukemia or other malignancies.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chromosomes, Human, Pair 2 / genetics*
  • Chromosomes, Human, Pair 3 / genetics*
  • Daunorubicin / administration & dosage
  • Female
  • Genes, Wilms Tumor
  • Humans
  • Induction Chemotherapy
  • Karyotype
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics*
  • Oncogene Proteins, Fusion / genetics
  • Remission Induction
  • Translocation, Genetic
  • Tretinoin / administration & dosage
  • Young Adult
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Oncogene Proteins, Fusion
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • Tretinoin
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Daunorubicin